Kim Jung Han, Kim Hyeong Su, Kim Bum Jun
Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea.
Department of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam 13574, Republic of Korea.
Oncotarget. 2017 Sep 11;8(43):75500-75508. doi: 10.18632/oncotarget.20824. eCollection 2017 Sep 26.
The alterations of have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or standard chemotherapy in patients with advanced or metastatic NSCLC. A systematic computerized search of the electronic databases was carried out. From seven studies, 2,577 patients were included in the meta-analysis. Compared with patients in the placebo group, patients who received an additional MET inhibitor did not show significantly improved progression-free survival (hazard ration (HR) = 0.92 [95% confidence interval (CI): 0.79-1.08], = 0.33) and overall survival (HR = 1.0 [95% CI: 0.90-1.11], = 0.97). In the subgroup analysis, patients with MET-high NSCLC tended to show longer survival when treated with an additional MET inhibitor than those in the placebo group (HR = 0.76, [95% CI: 0.58-1.01], = 0.06). In conclusion, this meta-analysis indicates that the addition of a MET inhibitor to an EGFR TKI or chemotherapy has no survival benefit over placebo in patients with advanced or metastatic NSCLC. Although patients with MET-high tumor tended to show better survival, further studies to explore more specific biomarkers are warranted to identify ideal candidates for MET inhibitors in NSCLC.
在非小细胞肺癌（NSCLC）中已检测到 的改变。然而，MET抑制剂的生存获益仍存在争议。我们进行了这项荟萃分析，以评估MET抑制剂联合表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）或标准化疗对晚期或转移性NSCLC患者的生存获益。对电子数据库进行了系统的计算机检索。从七项研究中，2577例患者被纳入荟萃分析。与安慰剂组患者相比，接受额外MET抑制剂治疗的患者无进展生存期（风险比（HR）=0.92 [95%置信区间（CI）：0.79-1.08]， =0.33）和总生存期（HR =1.0 [95%CI：0.90-1.11]， =0.97）均未显著改善。在亚组分析中，MET高表达的NSCLC患者在接受额外MET抑制剂治疗时的生存期往往比安慰剂组患者更长（HR =0.76，[95%CI：0.58-1.01]， =0.06）。总之，这项荟萃分析表明，在晚期或转移性NSCLC患者中，在EGFR-TKI或化疗基础上加用MET抑制剂与安慰剂相比并无生存获益。尽管MET高表达肿瘤患者的生存期往往更好，但仍需进一步研究以探索更特异的生物标志物，从而确定NSCLC中MET抑制剂的理想候选者。
